* If you want to update the article please login/register
Acute infections are the leading cause of acute COPD exacerbations, which often result in hospitalization in the winter, which often result in hospitalization. Any intervention that prevents or reduces bacterial infection in COPD, especially if it is not an antibiotic, would have major benefits for COPD patients, the NHS, and society as a whole. Many reasons may explain why COPD patients are more vulnerable to bacterial infections, according to it. When glucose levels in the lung are elevated, bacterial lung infection is more common. The investigators analyzed lung glucose levels in COPD patients and found that they are higher than those with COPD. Patients with elevated blood glucose levels had more bacteria in their lungs and sputum samples from COPD patients with higher glucose levels, which contributed to increased bacterial growth in the laboratory. Study Plan The proposed research will be a randomised, double-blinded, placebo-controlled, cross-over investigation of metformin in COPD patients. In those receiving placebo, the most notable result will be sputum glucose after three months' metformin therapy compared to sputum glucose in those taking placebo. A blood test will also be done to determine kidney and liver function, as well as blood glucose levels to rule out undiagnosed diabetes, kidney disease, or liver disease. Following a two-week washout period, the participants will switch to the other study arm for another 3 months and adhere to the same research protocol.
Source link: https://clinicaltrials.gov/ct2/show/NCT03651895
A treatment that either decreases the risk of lipofuscin accumulation or improves lipofuscin clearance in the RPE could also help avoid the degeneration associated with this condition. Objectives: The aim of this research is to investigate the safety and potential efficacy of oral metformin in reducing the rate of change in photoreceptor degeneration in ABCA4 retinopathy. Endpoints: Primary Endpoint: The difference in the growth rate of square-root transformed area of EZ band loss between the pre-treatment phase and the 24-month metformin treatment phase is shown by the following diagram: Primary Endpoint: The difference in the change in the growth rate of square-root transformed area of EZ band loss between the pre-treatment phase and the metformin treatment phase is shown by the endpoint: While the baseline to month 24 in BCVA total letters read, perimetry, and color fundus photography results show the change in the area of atrophy enlargement during the pre-treatment and 24 month metformin therapy phase, with a 30 percent decrease in growth rate of square-root AreaEZloss during the treatment phase relative to the pre-treatment period. Participants with Stargardt disease research currently enrolled in the NEI ABCA4 Natural History study, 12-EI-0203, will mainly be recruited from the population of participants with Stargardt disease in the NEI ABCA4 Natural History study, 12-EI-0203, but participants from outside this research will be considered mainly for inclusion criteria. Participants in Phase I/II of the National Institute of Health Clinical Center and University of Michigan Kellogg Eye Center are among the Enrolling Participants. This is a multi-center center, Phase I/II, prospective, open-label study to determine metformin as a potential treatment to reduce the risk of photoreceptor degeneration in ABCA4 retinopathy.
Source link: https://clinicaltrials.gov/ct2/show/NCT04545736
In overweight and obese people at risk of lung cancer, we will investigate the effects of metformin therapy on the expression of programmed cell death protein 1 on airway regulatory T cells. During the wait period, the estimated PD-1 expression of pulmonary Tregs in Cohort B changed by at least 1%. To investigate the effect of metformin on the immune profile of pulmonary parenchyma represented by bronchoalveolar lavage. To investigate the effect of metformin on serum adipokines and inflammatory cytokines. Participants are enrolled in metformin extended release orally for 26 weeks in the absence of unacceptable toxicity.
Source link: https://clinicaltrials.gov/ct2/show/NCT04931017
This is a phase four, open-label, single center study that seeks to determine the efficacy and safety of metformin for prevention, stabilization, or recovery of cardiac fibrosis in people who are homozygous for PAI-1 deficiency. Starting at a dose of 500 mg and increasing to a maximum of 2000 mg, a US-labeled oral metformin will be administered using the FDA-approved dosing regimen for diabetes mellitus type II. The Treated population will include subjects who receive metformin for at least 36 months. The study population will be divided into two groups: subjects who have failed to provide metformin or complete 36 months of metformin therapy, either due to intolerance to the study drug or for some other reason will be included in the Comparison group and will be followed clinically. The decision to continue metformin therapy beyond the study period in the metformin Therapy group will be based on drug safety, patient tolerability/preference, and provider discretion. The following individuals who are not currently receiving metformin Therapy are expected to switch between metformin therapy group and observation group in Metformin's case. Those who did not receive metformin treatment at any time during the study were treated differently than others who did not receive metformin therapy at any time during the study, or individuals who received metformin for a total of less than 36 months of therapy while on study i. e.
Source link: https://clinicaltrials.gov/ct2/show/NCT05317806
Medical records are reviewed and data collected through the hospital's electronic medical record, as well as clinical reports. Participants are women who underwent definitive treatment for endometrial cancer at WellSpan York Hospital's Department of Gynecologic Oncology between 2017 and 2019. Those patients with cancer recurrence were identified. Participants who took metformin vs. those that did not was determined were shown with a recurrence rate in participants that took metformin vs. those that did not. It is estimated that it takes time to endometrial cancer recurrence. A statistical analysis was done to determine each of these outcomes between participants who took metformin vs. those that did not.
Source link: https://clinicaltrials.gov/ct2/show/NCT05192850
Compare metformin to non-insulin diabetes drugs in terms of the primary safety issue of severe hypoglyce. Metformin is thought to be superior to sulfonylurea in terms of severe hypoglycemia symptoms and non-inferior to DPP-4 inhibitors, according to the primary hypothesis. With respect to HbA1c reduction, compare metformin to other non-insulin diabetes drugs for patients with T2DM and CKD. Metformin is expected to be superior to DPP-4 inhibitors and non-inferior to sulfonylureas for HbA1c reduction and improvement in blood sugar, according to the primary hypothesis, which is also improved in blood sugar. The heterogeneity of treatment effects on hypoglycemia risk and HbA1c response among patient subgroups is shown by the study. Completeness of Aim 4 data: Using the linked Medicare-CDRN registry, monitor completeness of CDRN data for opioids and hospitalization among Medicare beneficiaries. We'll use Medicare results from 2013-2016 to determine patients with T2DM type 2 diabetes mellitus and common diabetes drug use among Medicare patients with T2DM type 2 diabetes mellitus, and positive predictive value NPV, and positive predictive value PPV of INSIGHT CDRN results, as well as a gold standard and determine patients for whom NPV and PPV for hospitalizations and all major diabetes drug classes exceed 80%, with a gold standard. INSIGHT Both for the primary outcome and exposure to the drug of concern will be limited to Medicare patients identified by goal 1 as likely to exceed 80% NPV and PPV for the primary outcome and exposure to the drug of interest.
Source link: https://clinicaltrials.gov/ct2/show/NCT03921242
Women who suffer from PET are at a higher risk of hypertensive and cardiovascular diseases in later life and are more likely to die from premature death in later life. In addition, maternal age > 40 years and pregnancy interval > ten years raises the risk of PET by two to three folds respectively. Despite these risk factors, only a fraction of those at risk increase later develop PET as the new prediction criteria is not specific. An imbalance in pro-angiogenic factors, such as vascular endothelial growth factor and placental growth factor, has been blamed for the inadequate repair of spiral arteries in women who develop PET. VEGF protein expression has been greatly reduced under hypoxic conditions such as PET, growth factor signaling, and hormone secretion of sFlt-1. Metformin is hypothesized in obese type II diabetic women and gestational diabetics with poor glycemic control of diet, but it will not only reduce PET incidence, but also the PIGF/s-Flt-1 ratio in favor of normal pregnancies since metformin is now widely used to obese type II diabetic women and gestational diabetics with poor glycemic control.
Source link: https://clinicaltrials.gov/ct2/show/NCT04855513
In addition, gene expression changes in AMPK gene expression can be attributed to antitumor activity within the cell. Several studies had reported the effects of metformin on various cancer types of tumors. During remission induction phase in adolescents with newly diagnosed Acute Lymphoblastic Leukemia, the investigators explore if the metformin has any effect on ABCB1/MDR1 and AMPK. Hypothesis: If metformin is added to standard chemotherapy during the remission induction of Mexican adolescents with newly diagnosed acute lymphoblastic leukemia, the ABCB1 gene's mRNA expression levels will decrease and AMPK gene expression will rise at the time of remission induction. This report seeks to investigate the effect of metformin's addition to a standard chemotherapy regimen's increasing expression of the ABCB1 and AMPK genes during the remission induction of newly diagnosed adolescents with acute lymphoblastic leukemia in young adolescents with acute lymphoblastic leukemia. During the remission induction phase of the therapy, the investigators suggested a random open clinical trial to compare the changes of the ABCB1 and AMPK genes in adolescents with newly diagnosed acute lymphoblastic leukemia in patients receiving conventional chemotherapy versus conventional chemotherapy plus metformin 1000 mgm2SC per day. All patients with acute lymphoblastic leukemia ages 10 to 21 are eligible to participate, with informed consent approved. The intermediate variables are the peripheral blast count on day 0, morphology test of bone marrow on days 14 and at the end of induction and end of induction MRD.
Source link: https://clinicaltrials.gov/ct2/show/NCT05326984
In patients with advanced cancers resistant to standard therapy, the combination of sapanizertib and metformin can be evaluated for safety and tolerability, as well as the maximum tolerated dose. On days 15-42 of cycle 1, patients get metformin orally 1-3 times a day on days 1-42 and sapanisertib PO daily. On days 1-28 of cycle 2 and beyond, patients now receive metformin PO daily and sapanizertib PO daily.
Source link: https://clinicaltrials.gov/ct2/show/NCT03017833
Neoadjuvant therapy is the most common treatment for locally advanced breast cancer treatment and has been used in early breast cancer prevention. In terms of survival and overall disease progression, a meta-analysis concluded that there were no differences between neoadjuvant therapy and adjuvant therapy. Therefore, neoadjuvant therapy may be available as a standard treatment and as an alternative to adjuvant therapy to all patients who are likely to be candidates for adjuvant systemic chemotherapy. TAC regimens in breast cancer treatment have been widely accepted right now, as adjuvant or neoadjuvant chemotherapy regimens. A retrospective clinical analysis by MDACC showed a significant rise in pCR in diabetic breast cancer patients receiving metformin compared to diabetics not receiving metformin, as well as intermediate rates in non-diabetics who did not receive metformin, indicating that metformin may elevate the pCR rate with neoadjuvant chemotherapy.
Source link: https://clinicaltrials.gov/ct2/show/NCT01929811
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions